Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €17.04 EUR
Change Today +0.94 / 5.86%
Volume 51.0
HALOZ On Other Exchanges
Symbol
Exchange
Frankfurt
As of 3:44 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALOZ) Snapshot

Open
€15.91
Previous Close
€16.10
Day High
€17.25
Day Low
€15.91
52 Week High
06/3/15 - €17.25
52 Week Low
06/4/14 - €5.67
Market Cap
2.2B
Average Volume 10 Days
731.4
EPS TTM
--
Shares Outstanding
127.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALOZ)

halozyme therapeutics inc (HALOZ) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALOZ) Details

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxter Healthcare Corporation, Pfizer Inc., and Janssen Biotech, Inc. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

153 Employees
Last Reported Date: 03/2/15
Founded in 1998

halozyme therapeutics inc (HALOZ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.6M
Chief Financial Officer and Vice President
Total Annual Compensation: $364.9K
Compensation as of Fiscal Year 2014.

halozyme therapeutics inc (HALOZ) Key Developments

Halozyme Therapeutics, Inc. Announces Interim Findings from the Ongoing Phase 2 Clinical Study of Investigational Drug PEGPH20

Halozyme Therapeutics, Inc. announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer. The trial included 135 treated patients in stage 1, of whom a total of 44 patients - 23 receiving PEGPH20 in combination with ABRAXANE® and gemcitabine (PAG treatment arm) and 21 receiving ABRAXANE and gemcitabine alone (AG treatment arm) - had available biopsies that were determined in a retrospective analysis to have high levels of hyaluronan (HA). PEGPH20 targets HA to help improve cancer therapy access to tumor cells. Results reported include: A more than doubling of median progression-free survival of 9.2 months versus 4.3 months in high HA patients treated with PAG vs. AG (hazard ratio of 0.39; p-value of 0.05); A more than doubling of overall response rate of 52% against 24% (p-value of 0.038) and a duration of response of 8.1 months compared to 3.7 months in high HA patients treated with PAG versus AG; In the 30 high HA patients (15 PAG treatment arm versus 15 AG treatment arm) who were evaluated for response prior to the April 2014 clinical hold and subsequent PEGPH20 treatment discontinuation, the overall response rate was 73% against 27% (p-value of 0.01), respectively, consistent with findings presented in January; A trend toward improvement in median overall survival of 12 months compared to 9 months in high HA patients treated with PAG versus AG (hazard ratio of 0.62) despite discontinuation of PEGPH20 in more than half of the PAG-treated patients at the time of the clinical hold in April 2014.

Halozyme Therapeutics, Inc., Ventana Medical Systems, Inc. Enter into Global Agreement to Collaboratively Develop Companion Diagnostic for Cancer Treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc. announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan (HA). HA is a glycosaminoglycan – a chain of natural sugars distributed throughout human tissue – that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic (IVD), under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. This pharma collaboration is one of many at Ventana, where the Companion Diagnostics team is developing patient stratifying diagnostic tools that can help identify those individuals who are most likely to benefit from specific treatments. Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Halozyme Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Revenues for the first quarter of 2015 were $18.7 million, compared to $12.0 million for the first quarter of 2014. Revenues in the first quarter included $6.8 million in royalty revenue from sales of products under collaboration agreements, $6.1 million in product sales of bulk rHuPH20 for use in manufacturing collaboration products for Roche, $3.8 million in Hylenex recombinant (hyaluronidase human injection) product sales, and $2.0 million in collaboration revenues. The net loss for the first quarter of 2015 was $15.1 million, or $0.12 per basic and diluted share, compared to a net loss for the first quarter of 2014 of $26.5 million, or $0.22 per basic and diluted share. Operating loss was $13,911,000 compared to $25,219,000 a year ago. The company provided earnings guidance for the full year of 2015. For the full year 2015, the company reiterated its previously disclosed guidance of net revenues to be in the range of $85 million to $95 million. Net cash burn to be between $35 million to $45 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALOZ:GR €17.04 EUR +0.94

HALOZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $16.48 USD +0.69
Valeant Pharmaceuticals International Inc C$298.06 CAD +2.68
View Industry Companies
 

Industry Analysis

HALOZ

Industry Average

Valuation HALOZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.5x
Price/Book 60.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.